Gene expression profiling gets to the root of human hair follicle stem cells

George Cotsarelis

University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

Hair follicle stem cells sustain growth and cycling of the hair follicle and are located in the permanent portion of the follicle known as the bulge. In this issue of the JCI, Ohyama et al. report the characterization of global gene expression patterns of human hair follicle stem cells after their isolation using sophisticated laser capture techniques to microdissect out bulge cells (see the related article beginning on page 249). They discovered a panel of cell surface markers useful for isolating living hair follicle stem cells, a finding with potential therapeutic implications since isolated stem cells in mice can generate new hair follicles when transplanted to other mice. The findings of Ohyama et al. validate the use of the mouse for studying hair follicle biology but also underscore critical differences between mouse and human stem cell markers. In particular, CD34, which delineates hair follicle stem cells in the mouse, is not expressed by human hair follicle stem cells, while CD200 is expressed by stem cells in both species. Ultimately, this information will assist efforts to develop cell-based and cell-targeted treatments for skin disease.

Advances in stem cell biology have resulted in major clinical benefits. Bone marrow transplantation for treatment of cancers and corneal transplantation for treatment of blindness resulting from chemical burns were both possible because stem cells were identified and isolated from the affected tissues (1, 2). Many disorders of the skin, such as cancer, chronic wounds, skin atrophy and fragility, hirsutism, and alopecia, can be viewed as disorders of adult stem cells. Because stem cells in the epidermis and hair follicle serve as the ultimate source of cells for both of these tissues, understanding the control of their proliferation and differentiation is key to understanding disorders related to disruption in these processes. Furthermore, the isolation, cultivation, and propagation of epithelial stem cells are important for tissue-engineering approaches to treating skin disorders (3).

The skin possesses an outer covering produced by the epidermis that protects us from dehydration and from external environmental insults. The outer layer of the hair follicle is contiguous with the epidermis, forming invaginations that, in the case of scalp follicles, penetrate deeply into the fat underlying the skin. Approximately 5 million follicles that are spread over the body generate hair in a cyclical fashion. The duration of anagen (the period of hair growth), which varies from less than 60 to more than several thousand days on different body sites, determines the length of the hair shaft. After anagen, the follicle enters a stage of involution (catagen) and then a stage of

Nonstandard abbreviations used: K15, cytokeratin 15; LRC, label-retaining cell.

Conflict of interest: The author has declared that no conflict of interest exists.


Gene expression profiling gets to the root of human hair follicle stem cells

George Cotsarelis

University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

Hair follicle stem cells sustain growth and cycling of the hair follicle and are located in the permanent portion of the follicle known as the bulge. In this issue of the JCI, Ohyama et al. report the characterization of global gene expression patterns of human hair follicle stem cells after their isolation using sophisticated laser capture techniques to microdissect out bulge cells (see the related article beginning on page 249). They discovered a panel of cell surface markers useful for isolating living hair follicle stem cells, a finding with potential therapeutic implications since isolated stem cells in mice can generate new hair follicles when transplanted to other mice. The findings of Ohyama et al. validate the use of the mouse for studying hair follicle biology but also underscore critical differences between mouse and human stem cell markers. In particular, CD34, which delineates hair follicle stem cells in the mouse, is not expressed by human hair follicle stem cells, while CD200 is expressed by stem cells in both species. Ultimately, this information will assist efforts to develop cell-based and cell-targeted treatments for skin disease.

Advances in stem cell biology have resulted in major clinical benefits. Bone marrow transplantation for treatment of cancers and corneal transplantation for treatment of blindness resulting from chemical burns were both possible because stem cells were identified and isolated from the affected tissues (1, 2). Many disorders of the skin, such as cancer, chronic wounds, skin atrophy and fragility, hirsutism, and alopecia, can be viewed as disorders of adult stem cells. Because stem cells in the epidermis and hair follicle serve as the ultimate source of cells for both of these tissues, understanding the control of their proliferation and differentiation is key to understanding disorders related to disruption in these processes. Furthermore, the isolation, cultivation, and propagation of epithelial stem cells are important for tissue-engineering approaches to treating skin disorders (3).

The skin possesses an outer covering produced by the epidermis that protects us from dehydration and from external environmental insults. The outer layer of the hair follicle is contiguous with the epidermis, forming invaginations that, in the case of scalp follicles, penetrate deeply into the fat underlying the skin. Approximately 5 million follicles that are spread over the body generate hair in a cyclical fashion. The duration of anagen (the period of hair growth), which varies from less than 60 to more than several thousand days on different body sites, determines the length of the hair shaft. After anagen, the follicle enters a stage of involution (catagen) and then a stage of
rest (telogen), when the hair that was produced is now dead yet remains anchored in the follicle until it is shed during exogen (Figure 1).

Eventually, stem cells at the base of the resting follicle, in an area known as the bulge, proliferate and regenerate a new lower follicle including the highly proliferative bulb cells that produce a new hair (Figure 1). After giving rise to the new hair-producing cells, the stem cells return to a quiescent state that is a hallmark of these cells. Despite being surrounded by highly proliferating epidermal and hair follicle cells, the cells in the bulge rarely undergo mitosis. The extended state of dormancy is in line with other stem-like characteristics of these cells, including a prolonged lifespan — probably as long as that of the organism. This characteristic is thought to predispose these cells to tumor formation, since their long lifespan allows for accumulation of genetic mutations resulting from environmental insults such as UV irradiation or chemical carcinogens (4).

Identification of stem cells
Putative stem cells in mouse pelage (back skin) and vibrissa follicles were previously identified as quiescent cells in vivo by label-retaining cell (LRC) studies (5). Bulge cells in the adult mouse were then shown, through genetic labeling studies, to generate all of the cell lineages within the follicle in vivo and after isolation, and thus to function as stem cells (4). By transplantation of human scalp tissue to immunodeficient mice, LRCs in human follicles were localized to the basal layer of the outer root sheath in the area of the bulge (9). Because the human bulge is not morphologically apparent, markers were needed for the study of this area. Cyto- keratin 15 (K15), an intracellular intermediate filament protein, was identified as one marker preferentially expressed by the human bulge (9). Ideally, however, cell surface proteins against which antibodies could be raised would be valuable for isolating the human bulge cells, testing their stem cell characteristics, and defining global gene expression patterns important for understanding control mechanisms for stem cell growth and proliferation.

In this issue of the JCI, Ohyama et al. (10) report having defined the bulge area of the human hair follicle using a combination of proliferative characteristics,
Table 1
Selected genes upregulated in bulge cells compared with nonbulge epithelial cells

<table>
<thead>
<tr>
<th>Human</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD34</td>
<td>–</td>
</tr>
<tr>
<td>CD200</td>
<td>+</td>
</tr>
<tr>
<td>K15</td>
<td>+</td>
</tr>
<tr>
<td>ID2</td>
<td>+</td>
</tr>
<tr>
<td>DKK3</td>
<td>+</td>
</tr>
<tr>
<td>WIF1</td>
<td>+</td>
</tr>
<tr>
<td>FZD1 or FZD2</td>
<td>+</td>
</tr>
<tr>
<td>PHLD1</td>
<td>+</td>
</tr>
<tr>
<td>FOLLISTATIN</td>
<td>+</td>
</tr>
<tr>
<td>DIO2</td>
<td>+</td>
</tr>
<tr>
<td>CD71</td>
<td>–</td>
</tr>
</tbody>
</table>

Human and mouse bulge cells preferentially express many of the same genes, but critical differences were also discovered, as reported in this issue of the Journal of Clinical Investigation. In general, inhibitors of the WNT pathway, which is important for hair follicle cycling and differentiation, are increased. ID2, a gene previously associated with relatively undifferentiated cells, is upregulated in both species. Surprisingly, CD34, which is a specific bulge cell marker in the mouse, is lacking in human follicle stem cells. FOLLISTATIN and DIO2 are both in human but not mouse hair follicle bulge cells, and this may indicate their possible roles as mediators of hormonal pathways.

histological landmarks, and biochemical features. The location of quiescent LRCs in human scalp tissue grafted to immunodeficient mice was compared with the location of attachment of the arrector pili muscle (responsible for “goose bumps” upon contraction), which was identified using antibodies against smooth muscle. The LRCs were found at and above the site of muscle insertion up to the level of the sebaceous gland (Figure 1). The area containing the LRCs was also positive for K15, in contrast to the remainder of the outer root sheath, which is generally negative for this marker. K15 expression correlates with an immature phenotype within the skin, since it occurs in neonatal but not adult interfollicular epidermal cells (11), and thus reflects the distinct biochemical makeup of the bulge cells compared with the rest of the epidermis and hair follicle.

Searching for stem cell genes

Defining gene expression patterns that control the quiescent, noncycling nature of hair follicle stem cells is a major goal in epithelial stem cell biology, since it could lead to a better understanding of the abnormal proliferation that these cells undergo in the development of skin cancer (4). In addition, elucidation of genes involved in hair follicle stem cell proliferation and self-renewal may provide insights into alopecia and abnormal wound healing, since bulge cells are important for hair growth and normal wound healing (12). In order to identify genes related to the stem cell phenotype, Ohyama et al. (10) compared microarray gene expression profiles of bulge cells with those of other closely related cell populations within the hair follicle. Unlike in other microarray studies in which heterogeneous mixtures of cell types were used to generate mRNA, the use of laser capture microdissection, in which individual cells or groups of cells are dissected out under a microscope from tissue sections on a glass slide and captured using a laser, permitted isolation of a specific population of mRNA highly enriched for messages found in stem cells. Ohyama et al. discovered the presence of many of the same differentially expressed genes in the human bulge cells that were previously described in mouse bulge cells (4, 8); however, several key differences between the mouse and the human data were noted (Table 1). In particular, CD34, which is an excellent bulge cell marker in the mouse (13), is not present on human bulge cells. Rather, CD34 is expressed in slightly more differentiated outer root sheath cells below the bulge in the human follicle; therefore, antibodies against CD34 cannot be used to isolate human hair follicle stem cells. To circumvent this problem, Ohyama et al. (10) identified a panel of bulge stem cell surface markers, including some previously identified in the mouse (e.g., CD200; ref. 4). Using a combination of antibodies against these markers as well as negative markers for nonbulge cells, human hair follicle stem cells were successfully isolated and then propagated in culture, a feat that is a prerequisite to using these cells for tissue-engineering purposes and that up to now has been technically impossible (3).

Outside influences

The stem cell microenvironment or niche in the bulge appears to possess potent signals for maintaining stem cells in an undifferentiated state. In addition to epithelial stem cells, the bulge also contains other stem cell types, including melanocyte stem cells (14). That the stem cell niche is a unique microenvironment is supported by several lines of evidence. Interestingly, after an injury to the bulge cells causes apoptosis, the bulge can be repopulated by cells that are slightly more differentiated and reside at the base of the follicle, called the secondary germ (15). Presumably this is a function of the microenvironment in an effort to maintain the integrity of the bulge area by actually inducing cells that are direct descendents of stem cells to revert to a stem cell phenotype. Furthermore, the power of the niche evidently may instruct bone marrow–derived dendritic APCs to remain relatively undifferentiated (16), and even influence mast cells to remain in a precursor state (17).

The findings reported by Ohyama et al. (10) suggest that CD200 is an important regulator of the immune-privileged state of the hair follicle. This is in line with a previous study demonstrating that CD200 inhibits autoimmune inflammation in the hair follicle (18). This suggests that certain types of alopecia, such as lichen planopilaris, discoid lupus erythematosus, alopecia areata, and even androgenetic alopecia, with which inflammation appears to be associated, eventually could be treated with strategies aimed at augmenting CD200 expression.

The use of mouse models for studying human biology has been validated by these studies, with the caveat that findings from mouse and other animal models require confirmation in human systems. Because Ohyama et al.’s findings (10) are derived directly from human tissue, the significance of this line of research is greatly enhanced. By defining unique sets of cell surface markers for adult stem cells and other cell populations within the human follicle, investigators can now readily extract and study very specific follicular cell types for their ability to regenerate hair and skin, with the hope of developing novel methods for treating skin and hair disease.

Address correspondence to: George Cotarelis, University of Pennsylvania School of Medicine, M8 Stellar-Chance Laboratories, 422 Curie Boulevard, Philadelphia, Pennsylvania 19104, USA. Phone: (610) 902-2400; Fax: (215) 573-9102; E-mail: cotsarel@mail.med.upenn.edu.
Delving deeper into MALT lymphoma biology

Francesco Bertoni and Emanuele Zucca

Mucosa-associated lymphoid tissue (MALT) lymphomas can arise in a variety of extranodal sites. Interestingly, at least 3 different, apparently site-specific, chromosomal translocations, all affecting the NF-κB pathway, have been implicated in the development and progression of MALT lymphoma. The most common is the translocation t(11;18)(q21;q21), which results in the fusion of cIAP2 region on chromosome 11q21 with the MALT1 gene on chromosome 18q21 and is present in more than one-third of cases. The frequency of this translocation is site-related: common in the gastrointestinal tract and lung, rare in conjunctiva and orbit, and almost absent in salivary glands, thyroid, liver, and skin. In this issue of the JCI, Hu et al. add to our understanding of the molecular consequences of this translocation, showing that its fusion product, cIAP2-MALT1, may concomitantly contribute to lymphomagenesis both as a tumor suppressor gene and as an oncogene (see the related article beginning on page 174).

MALT lymphoma: the clinical background
Extranodal marginal zone B cell lymphoma (EMZL) of mucosa-associated lymphoid tissue (MALT), also known as MALT lymphoma, is a neoplastic disease that constitutes approximately 8% of all non-Hodgkin lymphomas (1–4). It can arise in a variety of extranodal sites and occurs most often in organs such as the stomach, the salivary glands, or the thyroid, where lymphocytes are normally absent. MALT is the result of chronic phlogistic events in response to either infectious conditions such as Helicobacter pylori–associated chronic gastritis, or autoimmune disorders like Hashimoto thyroiditis and myoeipithelial saladenitis. In these conditions abnormal B cell clones can progressively replace the normal B cell population of the inflammatory tissue, giving rise to the EMZL. Over 10 years ago, H. pylori was identified as an etiologic factor in gastric MALT lymphomas after the demonstration of tumor regression in the majority of early-stage cases treated with anti-Helicobacter antibiotic therapy, and this tumor therefore became a popular model of the close pathogenetic link between chronic inflammation and lymphoma development. Other bacterial infections were later possibly implicated in the pathogenesis of MALT lymphomas arising in the skin (Borrelia burgdorferi), in the ocular adnexa (Chlamydia psittaci), and in the small intestine (Campylobacter jejuni) (1, 4).

The prognosis for patients with MALT lymphomas is good; these tumors usually have an indolent course with overall 5-year survival rates greater than 80%, but rare cases with histologic transformation in cases of aggressive diffuse large-cell lymphoma have been described. It is nowadays generally accepted that eradication of H. pylori with antibiotics should be used as the sole initial treatment of localized gastric MALT lymphoma, while the use of anti-infectious treatment in nongastric locations is still under investigation. Other effective treatment approaches include radiotherapy, chemotherapy, and anti-CD20 mAbs (2, 3).

Many chromosomal translocations affecting the same pathway
Four main recurrent chromosomal translocations have been associated with the pathogenesis of EMZLs: t(11;18)(q21;q21), t(1;14)(p22;q32), (t,14)(q23;q21), and t(3;14)(p14.1;q32) (5–8) (Table 1). The latter is the most recently described and establishes the juxtaposition of the transcription factor FOXP1 next to the enhancer region.